The U.S. Supreme Court unanimously ruled in Hikma Pharmaceuticals USA v. Amarin Pharma that generic drug manufacturers cannot be held liable for patent infringement based on how pharmacists and doctors prescribe their products. The case centered on Vascepa, a branded drug with both patented and non-patented uses. When Hikma released a generic version, Amarin argued that Hikma should be responsible for infringement when the drug was used for patented cardiovascular indications.

The Federal Circuit had previously allowed Amarin’s claim to proceed, citing Hikma’s label, press releases, and website content as evidence of active inducement. But the Supreme Court disagreed, with Justice Ketanji Brown Jackson writing that these materials were consistent with legal compliance and standard industry practice. The Court stressed that describing a drug’s therapeutic category broadly—like calling a leukemia drug a 'cancer drug'—does not equate to encouraging patent infringement.

This decision reinforces a growing legal principle: companies shouldn’t face liability for the actions of third parties like doctors and pharmacists, especially when following state mandates. The ruling aligns with earlier precedent, such as Cox v. Sony, and underscores the need for clear evidence of intent to induce infringement. The outcome provides greater certainty for generic drugmakers navigating complex patent landscapes.